Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.
NCT00540111 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19
Last updated 2010-02-10
Summary
The purpose of this study was to assess the effect of soluble fiber® (partially hydrolyzed guar gum) supplementation on hypertriglyceridemia and immune profile in HIV-positive individuals on HAART.
Conditions
- Hypertriglyceridemia
- HIV Infections
Interventions
- DIETARY_SUPPLEMENT
-
soluble fiber® (partially hydrolyzed guar gum)
HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
Sponsors & Collaborators
-
Fundação de Amparo à Pesquisa do Estado de São Paulo
collaborator OTHER_GOV -
UPECLIN HC FM Botucatu Unesp
lead OTHER
Principal Investigators
-
Juliana Geraix, Nutricionist · Botucatu Medical School - UNESP
-
Paulo CM Pereira, PhD · Botucatu Medical School - UNESP
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-03-31
- Primary Completion
- 2007-07-31
- Completion
- 2007-10-31
More Related Trials
-
Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
NCT01874743 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
NCT01515813 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
NCT00122655 ·Status: TERMINATED ·Phase: PHASE4
-
Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)
NCT06317051 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
NCT00006412 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
NCT04442737 ·Status: COMPLETED ·Phase: PHASE4
-
Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
NCT01776151 ·Status: COMPLETED
-
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
NCT04644029 ·Status: TERMINATED ·Phase: PHASE3
-
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
NCT05652478 ·Status: RECRUITING ·Phase: PHASE2
-
Raltegravir Therapy for Women With HIV and Fat Accumulation
NCT00656175 ·Status: COMPLETED ·Phase: PHASE2
-
Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)
NCT00117494 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
NCT00454337 ·Status: COMPLETED ·Phase: PHASE3
-
Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation
NCT02771054 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-HIV Medications for People Recently Infected With HIV
NCT00106171 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
NCT00515827 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
NCT05898841 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Omacor on Triglycerides in HIV Infected Subjects
NCT00598910 ·Status: TERMINATED ·Phase: PHASE4
-
Pilot Study of Raltegravir Lipodystrophy IISP
NCT01164605 ·Status: UNKNOWN ·Phase: NA
-
Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti
NCT00120510 ·Status: COMPLETED ·Phase: NA
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)
NCT03447873 ·Status: COMPLETED ·Phase: PHASE4
-
Post Analytic Treatment Interruption Study
NCT02761200 ·Status: RECRUITING
-
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
NCT00517569 ·Status: UNKNOWN ·Phase: PHASE1
-
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
NCT00843661 ·Status: UNKNOWN ·Phase: PHASE4
-
An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
NCT01541085 ·Status: COMPLETED